Headlines about Hill-Rom (NYSE:HRC) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hill-Rom earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical technology company an impact score of 45.6818393335863 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- Hill-Rom’s (HRC) Buy Rating Reaffirmed at Barclays (americanbankingnews.com)
- Hill-Rom (HRC) Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Hill-Rom Holdings (HRC) Prelim. Q1 Revenue Tops Views (streetinsider.com)
- Hill-Rom Announces Preliminary Fiscal First Quarter Financial Results And Comments On Expected Impact Of New U.S. Tax Reform Legislation (finance.yahoo.com)
- Hill-Rom (HRC) Updates Q1 Earnings Guidance (americanbankingnews.com)
A number of research analysts recently issued reports on HRC shares. KeyCorp reiterated a “buy” rating and set a $89.00 target price (up previously from $82.00) on shares of Hill-Rom in a research report on Sunday, November 5th. ValuEngine downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Raymond James Financial upgraded shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price target for the company in a research note on Wednesday, January 3rd. Zacks Investment Research lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. Finally, Stifel Nicolaus restated a “buy” rating and set a $92.00 price target on shares of Hill-Rom in a research note on Wednesday, November 29th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $93.00.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 EPS for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.05. The business had revenue of $738.30 million during the quarter, compared to analyst estimates of $731.10 million. Hill-Rom had a net margin of 9.36% and a return on equity of 21.07%. Hill-Rom’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 EPS. research analysts anticipate that Hill-Rom will post 4.32 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 15th were paid a dividend of $0.18 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $0.72 dividend on an annualized basis and a yield of 0.83%. Hill-Rom’s dividend payout ratio (DPR) is presently 36.18%.
In other news, CEO John J. Greisch sold 125,241 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the completion of the sale, the chief executive officer now owns 280,851 shares in the company, valued at approximately $23,195,484.09. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total transaction of $82,990.00. Following the completion of the sale, the senior vice president now owns 1,066 shares of the company’s stock, valued at approximately $88,467.34. The disclosure for this sale can be found here. Insiders have sold a total of 226,241 shares of company stock valued at $18,708,644 in the last 90 days. 2.20% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Hill-Rom (HRC) Given Media Impact Score of 0.17” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/12/hill-rom-hrc-given-media-impact-score-of-0-17.html.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.